S&P/ASX 200 Tipped To Rise
Rask Invest Research Team
February 14, 2018
The Australian share market, or S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO), is expected
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The Australian share market, or S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO), is expected
CSL Limited (ASX:CSL) tried its best to inject some enthusiasm
Australia’s share market, or the All Ordinaries (INDEXASX: XAO)(ASX: XAO),
Immunology giant CSL Limited (ASX:CSL) reported its half-year results on
The Australian share market, or S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO), is expected
CSL Limited (ASX:CSL) shares lifted Australia’s S&P/ASX 200 (INDEXASX:XJO) (ASX:XJO)
The ALL ORDINARIES (INDEXASX:XAO)(ASX:XAO) index fell 1% on Friday, as
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Unsubscribe anytime. Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.